Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Veracyte (VCYT) over the last 14 years, with Q3 2025 value amounting to $2.8 million.

  • Veracyte's Capital Expenditures rose 2453.17% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 409.62%. This contributed to the annual value of $11.3 million for FY2024, which is 1331.19% up from last year.
  • As of Q3 2025, Veracyte's Capital Expenditures stood at $2.8 million, which was up 2453.17% from $1.3 million recorded in Q2 2025.
  • Veracyte's Capital Expenditures' 5-year high stood at $4.1 million during Q4 2024, with a 5-year trough of $841000.0 in Q4 2021.
  • In the last 5 years, Veracyte's Capital Expenditures had a median value of $2.1 million in 2024 and averaged $2.2 million.
  • Per our database at Business Quant, Veracyte's Capital Expenditures skyrocketed by 18535.43% in 2021 and then plummeted by 5357.4% in 2025.
  • Veracyte's Capital Expenditures (Quarter) stood at $841000.0 in 2021, then soared by 122.59% to $1.9 million in 2022, then surged by 33.39% to $2.5 million in 2023, then soared by 65.84% to $4.1 million in 2024, then plummeted by 32.58% to $2.8 million in 2025.
  • Its Capital Expenditures stands at $2.8 million for Q3 2025, versus $1.3 million for Q2 2025 and $1.8 million for Q1 2025.